MicroRNA-133a functions as a tumor suppressor by targeting IGF-1R in hepatocellular carcinoma

Tumor Biology

Volumn 36, Issue 12, 2015, Pages 9779-9788

  Zhang, Wei ^a   Liu, Kai ^a   Liu, Songyang ^a   Ji, Bai ^a   Wang, Yingchao ^a   Liu, Yahui ^a  

^a THE FIRST HOSPITAL OF JILIN UNIVERSITY   (China)

Author keywords

Hepatocellular carcinoma; IGF 1R; MicroRNAs; miR 133a

Indexed keywords

MICRORNA; MICRORNA 133A; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN KINASE B; SOMATOMEDIN C RECEPTOR; UNCLASSIFIED DRUG; MIRN133 MICRORNA, HUMAN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER STAGING; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; COLONY FORMATION; CONTROLLED STUDY; DOWN REGULATION; ENZYME INHIBITION; FEMALE; G1 PHASE CELL CYCLE CHECKPOINT; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LYMPH NODE METASTASIS; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; TUMOR DIFFERENTIATION; ANIMAL; BIOSYNTHESIS; CELL MOTION; DRUG SCREENING; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; LIVER TUMOR; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

ANIMALS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; MICE; MICRORNAS; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84952870732     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-3749-8     Document Type: Article

References (40)

1. Waly Raphael S, Yangde Z, Yuxiang C. Hepatocellular carcinoma: focus on different aspects of management. ISRN Oncol. 2012;2012:421673.
2. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–55.
3. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology. 2004;127:S5–16.
4. Zhou YM, Zhang XF, Yu F, Liu XB, Wu LP, Li B, et al. Efficacy of surgical resection for pulmonary metastases from hepatocellular carcinoma. Med Sci Monit Int Med J Exp Clin Res. 2014;20:1544–9.
5. Raza A, Sood GK. Hepatocellular carcinoma review: current treatment, and evidence-based medicine. World J Gastroenterol WJG. 2014;20:4115–27.
6. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116:281–97.
7. Brennecke J, Hipfner DR, Stark A, Russell RB, Cohen SM. Bantam encodes a developmentally regulated microRNA that controls cell proliferation and regulates the proapoptotic gene hid in Drosophila. Cell. 2003;113:25–36.
8. Sun K, Lai EC. Adult-specific functions of animal microRNAs. Nat Rev Genet. 2013;14:535–48.
9. Shenouda SK, Alahari SK. MicroRNA function in cancer: oncogene or a tumor suppressor? Cancer Metastasis Rev. 2009;28:369–78.
10. Zhang X, Han C, He J. Research progress of oncogene and tumor suppressor gene in bladder cancer. Panminerva Med. 2015.
11. Tian T, Wang J, Zhou X. A review: microRNA detection methods. Org Biomol Chem. 2015;13:2226–38.
12. Saumet A, Mathelier A, Lecellier CH. The potential of microRNAs in personalized medicine against cancers. BioMed Res Int. 2014;2014:642916.
13. Cheng G. Circulating miRNAs: roles in cancer diagnosis, prognosis and therapy. Adv Drug Deliv Rev. 2015;81:75–93.
14. Hayes J, Peruzzi PP, Lawler S. MicroRNAs in cancer: biomarkers, functions and therapy. Trends Mol Med. 2014;20:460–9.
15. Yu H, Lu Y, Li Z, Wang Q. MicroRNA-133: expression, function and therapeutic potential in muscle diseases and cancer. Curr Drug Targets. 2014;15:817–28.
16. Feng Y, Niu LL, Wei W, Zhang WY, Li XY, Cao JH, et al. A feedback circuit between miR-133 and the erk1/2 pathway involving an exquisite mechanism for regulating myoblast proliferation and differentiation. Cell Death Dis. 2013;4:e934.
17. Kojima S, Chiyomaru T, Kawakami K, Yoshino H, Enokida H, Nohata N, et al. Tumour suppressors miR-1 and miR-133a target the oncogenic function of purine nucleoside phosphorylase (PNP) in prostate cancer. Br J Cancer. 2012;106:405–13.
18. Chiyomaru T, Enokida H, Tatarano S, Kawahara K, Uchida Y, Nishiyama K, et al. miR-145 and miR-133a function as tumour suppressors and directly regulate fscn1 expression in bladder cancer. Br J Cancer. 2010;102:883–91.
19. Nohata N, Hanazawa T, Kikkawa N, Mutallip M, Fujimura L, Yoshino H, et al. Caveolin-1 mediates tumor cell migration and invasion and its regulation by miR-133a in head and neck squamous cell carcinoma. Int J Oncol. 2011;38:209–17.
20. Kano M, Seki N, Kikkawa N, Fujimura L, Hoshino I, Akutsu Y, et al. miR-145, miR-133a and miR-133b: tumor-suppressive miRNAs target fscn1 in esophageal squamous cell carcinoma. Int J Cancer. 2010;127:2804–14.
21. Dong Y, Zhao J, Wu CW, Zhang L, Liu X, Kang W, et al. Tumor suppressor functions of miR-133a in colorectal cancer. Mol Cancer Res MCR. 2013;11:1051–60.
22. Ma J, Wang T, Guo R, Yang X, Yin J, Yu J, et al. Involvement of miR-133a and miR-326 in ADM resistance of HepG2 through modulating expression of abcc1. J Drug Target. 2015;25:1–6.
23. Wan TM, Lam CS, Ng L, Chow AK, Wong SK, Li HS, et al. The clinicopathological significance of miR-133a in colorectal cancer. Dis Markers. 2014;2014:919283.
24. Chun YS, Huang M, Rink L, Von Mehren M. Expression levels of insulin-like growth factors and receptors in hepatocellular carcinoma: a retrospective study. World J Surg Oncol. 2014;12:231.
25. Wu J, Zhu AX. Targeting insulin-like growth factor axis in hepatocellular carcinoma. J Hematol Oncol. 2011;4:30.
26. Osaki LH, Gama P. MAPKs and signal transduction in the control of gastrointestinal epithelial cell proliferation and differentiation. Int J Mol Sci. 2013;14:10143–61.
27. Cao Z, Liu LZ, Dixon DA, Zheng JZ, Chandran B, Jiang BH. Insulin-like growth factor-I induces cyclooxygenase-2 expression via PI3K, MAPK and PKC signaling pathways in human ovarian cancer cells. Cell Signal. 2007;19:1542–53.
28. Oishi N, Yamashita T, Kaneko S. Molecular biology of liver cancer stem cells. Liver Cancer. 2014;3:71–84.
29. Khare S, Zhang Q, Ibdah JA. Epigenetics of hepatocellular carcinoma: role of microRNA. World J Gastroenterol WJG. 2013;19:5439–45.
30. Gramantieri L, Fornari F, Callegari E, Sabbioni S, Lanza G, Croce CM, et al. MicroRNA involvement in hepatocellular carcinoma. J Cell Mol Med. 2008;12:2189–204.
31. Negrini M, Gramantieri L, Sabbioni S, Croce CM. MicroRNA involvement in hepatocellular carcinoma. Anti Cancer Agents Med Chem. 2011;11:500–21.
32. Qiu T, Zhou X, Wang J, Du Y, Xu J, Huang Z, et al. miR-145, miR-133a and miR-133b inhibit proliferation, migration, invasion and cell cycle progression via targeting transcription factor Sp1 in gastric cancer. FEBS Lett. 2014;588:1168–77.
33. Mataki H, Enokida H, Chiyomaru T, Mizuno K, Matsushita R, Goto Y, et al. Downregulation of the microRNA-1/133a cluster enhances cancer cell migration and invasion in lung-squamous cell carcinoma via regulation of coronin1c. J Hum Genet. 2015;60:53–61.
34. Ji F, Zhang H, Wang Y, Li M, Xu W, Kang Y, et al. MicroRNA-133a, downregulated in osteosarcoma, suppresses proliferation and promotes apoptosis by targeting Bcl-xl and Mcl-1. Bone. 2013;56:220–6.
35. King H, Aleksic T, Haluska P, Macaulay VM. Can we unlock the potential of IGF-1R inhibition in cancer therapy? Cancer Treat Rev. 2014;40:1096–105.
36. Scharf JG, Braulke T. The role of the igf axis in hepatocarcinogenesis. Horm Metab Res Horm Stoffwechselforschung Horm Metab. 2003;35:685–93.
37. Singh P, Alex JM, Bast F. Insulin receptor (IR) and insulin-like growth factor receptor 1 (IGF-1R) signaling systems: novel treatment strategies for cancer. Med Oncol. 2014;31:805.
38. Wang LK, Hsiao TH, Hong TM, Chen HY, Kao SH, Wang WL, et al. MicroRNA-133a suppresses multiple oncogenic membrane receptors and cell invasion in non-small cell lung carcinoma. PLoS One. 2014;9:e96765.
39. Gong Y, Ren J, Liu K, Tang LM. Tumor suppressor role of miR-133a in gastric cancer by repressing IGF1R. World J Gastroenterol WJG. 2015;21:2949–58.
40. Guo T, Feng Y, Liu Q, Yang X, Jiang T, Chen Y, et al. MicroRNA-320a suppresses in GBM patients and modulates glioma cell functions by targeting IGF-1R. Tumour Biol J Int Soc Oncodevelopmental Biol Med. 2014;35:11269–75.